Literature DB >> 23600881

HA2 glycopolypeptide of influenza A virus and antiviral immunity.

E Varečková1, V Mucha, F Kostolanský.   

Abstract

Influenza A viruses (IAVs) cause acute respiratory infections in humans against which an effective prevention has not yet been developed due to their high variability and broad host specificity. The permanent threat of arising new influenza pandemic is represented by avian viruses which after their interspecies transmission can cause a disease with a devastating impact on humans lacking the specific immunity. Since the current vaccines inducing virus-neutralizing (VN) antibodies are targeted at a variable globular part of hemagglutinin (HA), their efficacy is limited and they need permanent updating. On the other hand, conserved IAV antigens such as proton channel M2, membrane protein M1 or nucleoprotein (NP) do not induce VN antibodies, but they do induce heterosubtypic protection resulting in the reduction of virus replication and an improved recovery from the disease. From this point of view recent attention has also been focused on the conserved part of HA, its HA2 glycoprotein (HA2). The main aspects revealing a contribution of HA2 gp to protective immunity are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23600881     DOI: 10.4149/av_2013_02_247

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  4 in total

Review 1.  The Contribution of Viral Proteins to the Synergy of Influenza and Bacterial Co-Infection.

Authors:  Miriam Mikušová; Karolína Tomčíková; Katarína Briestenská; František Kostolanský; Eva Varečková
Journal:  Viruses       Date:  2022-05-16       Impact factor: 5.818

2.  Biological properties of influenza A virus mutants with amino acid substitutions in the HA2 glycoprotein of the HA1/HA2 interaction region.

Authors:  L Jakubcová; M Vozárová; J Hollý; K Tomčíková; M Fogelová; K Polčicová; F Kostolanský; E Fodor; E Varečková
Journal:  J Gen Virol       Date:  2019-09       Impact factor: 3.891

3.  Generation of an avian influenza DIVA vaccine with a H3-peptide replacement located at HA2 against both highly and low pathogenic H7N9 virus.

Authors:  Gang Li; Juan Feng; Keji Quan; Zhihao Sun; Yuncong Yin; Yinyan Yin; Sujuan Chen; Tao Qin; Daxin Peng; Xiufan Liu
Journal:  Virulence       Date:  2022-12       Impact factor: 5.882

4.  Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes.

Authors:  X Fan; A M Hashem; Z Chen; C Li; T Doyle; Y Zhang; Y Yi; A Farnsworth; K Xu; Z Li; R He; X Li; J Wang
Journal:  Mucosal Immunol       Date:  2014-07-23       Impact factor: 7.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.